Astec Lifesciences Ltd
Astec Lifesciences is a B2B agrochemical active-ingredient (technical) manufacturer, producing fungicide, herbicide and insecticide actives, bulk & formulations, and chemical intermediates. It is a recognised global leader in triazole fungicides (tebuconazole, propiconazole, hexaconazole and similar molecules) and runs a growing Contract Development & Manufacturing (CDMO/CSM) business serving innovator clients in Europe, Japan and the US. The company sells across ~24 countries and operates purely B2B — it has no consumer brand exposure.
Astec became a subsidiary of Godrej Agrovet Ltd (GAVL) in 2015; GAVL has since steadily raised its stake, most recently participating in a ₹238 Cr rights issue (July 2025) to lift promoter holding to ~72%. The company is positioned at the molecule-synthesis layer of the crop-protection value chain — converting basic and advanced intermediates into registered technicals that downstream formulators and innovators sell to farmers.
Revenue Segments (FY26 growth)
Enterprise (own products)
Triazole fungicide technicals & formulations — the legacy core. Revenue +68.2% YoY in FY26 as channel destocking eased and volumes/price-mix recovered. Domestic sales surged +133.8% in Q4FY26.
Contract Manufacturing / CDMO
Custom synthesis for innovator clients (Europe/Japan/US). Revenue +85.7% YoY in FY26. Higher-margin, stickier multi-year relationships; the strategic growth engine alongside the new Mahad capacity.
Moat Assessment (qualitative — not a guarantee of future performance)
| Moat Type | Evidence | Durability |
|---|---|---|
| Intangibles / IP | Global leadership in triazole chemistry; complex multi-step synthesis know-how & registrations | Moderate-Strong |
| Switching cost | CDMO clients qualify processes over years; regulatory re-registration deters switching | Moderate |
| Parent backing | Godrej Agrovet capital + distribution; balance-sheet support through the cycle | Strong |
| Cost / scale | Sub-scale vs PI Industries / UPL; operating leverage still being built at Mahad | Weak (for now) |
Manufacturing footprint
Multi-plant technical synthesis (Maharashtra). New Mahad facility expands capacity and product range; targeting 70%+ utilisation to deliver operating leverage on recent capex.
Triazole leadership
Core competence in multi-step triazole fungicide synthesis — a complex, registration-heavy category with limited credible global suppliers.
CDMO scale-up
Building a multi-year custom-synthesis order book with innovators — the higher-margin, less-cyclical growth lever.
Mahad capacity ramp (illustrative)
Utilisation ramp is the key operating-leverage driver — every incremental point of utilisation on the depreciated asset base flows disproportionately to EBITDA.
Strategic priorities
1 · Deleverage
₹247 Cr of rights proceeds applied to debt repayment; D/E cut to 1.15x.
2 · Mix shift to CDMO
Grow contract manufacturing share to dampen agrochem cyclicality.
3 · Restore margins
Volume recovery + Mahad operating leverage to rebuild OPM toward historical ~18-23%.
The investable thesis is a cyclical recovery from a destocking trough, layered on a structural shift toward Indian agrochemical CDMO. The global crop-protection industry endured a severe channel-inventory de-stocking cycle through CY2023–CY2025 that crushed technical-maker volumes and prices; FY26 marks the inflection where volumes and pricing began normalising — visible in Astec's +33% YoY Q4FY26 revenue and return to positive EBITDA.
Tailwind 1 — Destock ending
Global agrochem channel inventory normalising; technical demand and pricing recovering off multi-year lows.
Tailwind 2 — China+1 CDMO
Innovators diversifying custom-synthesis away from China; India a preferred alternative — directly benefits Astec's CDMO book.
Tailwind 3 — Parent leverage
Godrej Agrovet capital, governance and crop-protection ecosystem de-risk the recovery runway.
Near-term (0–12M)
Revenue recovery continues; quarterly losses narrow toward break-even as utilisation rises.
Medium-term (1–3Y)
Return to sustained profitability; OPM rebuild; CDMO mix higher. The core re-rating window.
Long-term (3Y+)
Mid-teens-plus ROCE if CDMO scales and triazole cycle normalises — back toward FY22 earnings power.
| Project / Asset | Detail | Status |
|---|---|---|
| Mahad facility | Capacity & product-range expansion; funded by FY24-25 debt-led capex (long-term debt rose to ~₹280 Cr Mar-25) | Ramping — 70%+ util target |
| Debt repayment | ₹247 Cr of ₹238 Cr rights proceeds applied to borrowings + commercial paper | Completed FY26 |
| CWIP | Fell to ₹0 Cr in FY26 (from ₹165 Cr FY24) — major capex cycle complete | Capex peak passed |
Astec's P&L tells a textbook cyclical story: a FY20→FY22 up-cycle (revenue ₹523→₹677 Cr, OPM 16%→23%, PAT ₹48→₹90 Cr) followed by a brutal FY23→FY25 destocking collapse into deep losses (FY25 PAT −₹135 Cr, OPM −17%). FY26 is the inflection — revenue rebounded +17.6% to ₹448 Cr and full-year EBITDA turned marginally positive, though the company remains net-loss-making at the PAT level due to higher interest and depreciation on the expanded asset base.
Revenue (₹Cr) & YoY %
EBITDA (₹Cr) & OPM %
PAT (₹Cr) & PAT Margin %
EPS (₹) & ROCE %
Source: Screener.in standalone data, FY15–FY26. FY26 = year ended Mar 2026.
| Factor | Relevance to Astec | Direction |
|---|---|---|
| China+1 / supply diversification | Innovators shifting custom synthesis out of China — tailwind for Indian CDMO capacity | Positive |
| CIB&RC registrations | Technical registrations are a barrier to entry but add lead-time/cost for new molecules | Neutral |
| Environmental / effluent norms | Tightening pollution-control compliance raises capex & opex for chemical plants | Neutral-Negative |
| Global MRL / molecule bans | Triazole molecules face periodic regulatory review in EU — product-concentration risk | Watch |
No India PLI scheme is specific to agrochemical technicals; the principal regulatory swing factor is global registration/MRL policy on triazole molecules. Research framing only.
Astec is a small-cap with limited sell-side coverage given its loss-making phase. Available commentary (MarketsMojo, Whalesbook result analyses) frames FY26 as "losses narrowing but fundamental challenges persist" — acknowledging the revenue recovery (+17% FY26) and positive EBITDA turn, while flagging continued PAT losses, high debtor days and rich book multiple. Consensus themes analysts are tracking:
Bull thread
Volume recovery in Enterprise & CDMO, Mahad operating leverage, deleveraged balance sheet, parent backing, end of destocking.
Bear thread
Still loss-making, negative operating cash flow, ballooning debtor days (202), valuation rich vs negative returns, triazole concentration.
Source: public analyst & result-analysis reports — research framing only, not a recommendation. No explicit revenue/EPS consensus or price targets reproduced.
| Item (₹Cr) | FY26 (Mar-26) | FY25 (Mar-25) |
|---|---|---|
| Equity Capital | 22 | 20 |
| Reserves | 368 | 215 |
| Net Worth | ~391 | ~235 |
| Borrowings | 449 | 555 |
| Debt / Equity | 1.15x | 2.36x |
| Fixed Assets | 478 | 499 |
| CWIP | 0 | 21 |
| Cash from Operations (CFO) | −81 | −8 |
| Free Cash Flow | −86 | −24 |
Fraud / Quality Filter
🔴 Receivable days
202 days in FY26 (up from 141) — sharp rise; partly recovery-phase rebuild, but a clear stress flag.
⚠️ Inventory days
169 days — elevated vs revenue, though down from FY23 peak of 268. Watch.
🔴 CFO / PAT
Negative CFO with PAT loss — cash conversion poor through the down-cycle. Working-capital absorption.
✅ Promoter pledge
No material pledge flagged; promoter (Godrej) raising stake — clean.
✅ Auditor
No adverse auditor change flagged; Godrej-group governance.
✅ Related-party
Parent transactions exist (group company) but within disclosed governance norms — monitor.
| Quarter | Revenue ₹Cr | YoY% | OPM% | PAT ₹Cr | EPS ₹ |
|---|---|---|---|---|---|
| Q4 FY26 (Mar-26) | 158.6 | +32.7 | 5.77 | −7.8 | −3.48 |
| Q3 FY26 (Dec-25) | 124.7 | +22.6 | 3.19 | −15.7 | −7.05 |
| Q2 FY26 (Sep-25) | 73.7 | −25.2 | −9.07 | −24.4 | −10.96 |
| Q1 FY26 (Jun-25) | 91.1 | +31.3 | −12.07 | −33.0 | −14.75 |
| Q4 FY25 (Mar-25) | 119.5 | — | 4.63 | −16.1 | −7.18 |
| Q3 FY25 (Dec-24) | 93.9 | — | −6.12 | −40.4 | −18.03 |
Revenue last 6Q (₹Cr)
OPM % last 6Q
With negative trailing earnings, P/E is not meaningful. The market is valuing Astec on through-cycle / recovery earnings power and book value: at ₹771 the stock trades at ~4.4x book (BV ₹175) — a premium to a loss-making, negative-ROE business, reflecting embedded recovery optionality and the Godrej-parent quality premium. EV/Sales sits around ~4.8x on ₹448 Cr revenue (mkt cap ₹1,721 Cr + ~₹449 Cr debt).
| Metric | Current | Context |
|---|---|---|
| P/B | 4.4x | Premium vs negative ROE — prices in recovery |
| P/E | N/A | Negative EPS −₹36.3 (TTM) |
| EV/Sales (approx) | ~4.8x | Elevated for a technicals maker at trough margins |
| EV/EBITDA | N/M | EBITDA ~breakeven FY26 |
Peer Comparison (Screener peer set)
| Company | Mkt Cap ₹Cr | P/E | ROCE% | Latest Qtr Sales YoY% |
|---|---|---|---|---|
| UPL | 54,411 | 28.8 | 10.2 | +17.7 |
| PI Industries | 42,086 | 33.9 | 14.7 | −12.4 |
| Sumitomo Chemical India | 25,035 | 45.2 | 23.5 | +1.0 |
| Bayer CropScience | 20,260 | 29.4 | 29.1 | +5.2 |
| Dhanuka Agritech | 5,115 | 17.8 | 24.0 | +9.4 |
| Rallis India | 4,714 | 23.4 | 14.1 | +6.1 |
| Astec Lifesciences | 1,721 | N/A | −5.5 | +32.7 |
| Median (24 co.) | 1,958 | 23.2 | 15.3 | +11.4 |
Astec is the smallest, only loss-making name in the set — but posted the highest sales-recovery rate (+32.7% YoY). Source: Screener peers. Research framing only.
As a technicals + CDMO maker, Astec does not report a formal "order book" the way EPC companies do. The demand proxy is volume growth and CDMO commercialisations. FY26 demand signals were strongly positive: Enterprise volumes +68% YoY, CDMO +86% YoY, domestic +134% in Q4.
Promoter / Parent
Godrej Agrovet (71.97%) — professional, well-governed agri-conglomerate. Demonstrated commitment by funding the ₹238 Cr rights issue and lifting stake through the trough — a high-quality skin-in-the-game signal.
Board / leadership
FY26 results filing included AGM scheduling and board changes/reshuffle (per exchange disclosures). Management transition is in progress — monitor continuity of CDMO strategy.
Walk vs Talk — Guidance Accuracy
| Theme | Said | Delivered | Read |
|---|---|---|---|
| Recovery in H2 FY26 | Volumes to improve as destock ends | Q3/Q4 rev +23%/+33% YoY, OPM positive | ✅ Hit |
| Deleverage via rights | Use proceeds to cut debt | D/E 2.36→1.15; ₹247 Cr repaid | ✅ Hit |
| Return to profitability | Margin rebuild on volumes | EBITDA positive but PAT still loss | ⚠️ Partial |
| Working capital control | — | Debtor days rose to 202; CFO negative | 🔴 Miss |
Guidance accuracy: 🟡 Adequate — operational recovery delivered as signalled, but cash conversion and PAT break-even remain unproven.
Still loss-making HIGH
PAT negative for 3 straight years (FY24-26). Profitability inflection is signalled but not yet proven at the bottom line.
Mitigant: EBITDA positive, losses narrowing each quarter.
Working capital stress HIGH
Debtor days 202, CCC 263, negative CFO (−₹81 Cr). Cash absorption even as revenue recovers.
Mitigant: post-rights liquidity; receivables should normalise with volumes.
Valuation vs returns HIGH
4.4x book on negative ROE prices in a full recovery; downside if the turn stalls.
Mitigant: through-cycle earnings power + scarcity of triazole capacity.
Triazole concentration MED
Heavy reliance on triazole fungicide chemistry exposes it to molecule-specific pricing & MRL/regulatory risk.
Mitigant: CDMO diversification underway.
Agrochem cyclicality MED
Technical pricing is cyclical and partly set by global oversupply / China competition.
Mitigant: China+1 CDMO shift; parent support.
CDMO order lumpiness MED
Custom-synthesis revenue is order-timing dependent; quarters can be volatile (Q2FY26 −25%).
Mitigant: multi-year client qualification stickiness.
| Milestone | Watch For | Timeline | Why It Matters |
|---|---|---|---|
| PAT break-even | A quarterly PAT ≥ 0 | FY27 (H1) | Confirms the turnaround at the bottom line, not just EBITDA |
| OPM rebuild | Sustained OPM >10% for 2+ quarters | FY27 | Signals operating leverage from Mahad ramp |
| Debtor-day normalisation | Receivables back toward ~130-140 days | FY27 | Validates cash conversion / quality of recovery |
| Positive operating cash flow | CFO turning positive FY27 | FY27 | Removes the funding overhang |
| CDMO contract wins | Disclosure of new multi-year custom-synthesis deals | Ongoing | De-risks revenue mix & cyclicality |
These are research tracking signals — not signals to act.
Ownership trend (last 8Q)
Smart-money read
Promoter (Godrej): 66.75% → 71.97% — raised through the down-cycle via the rights issue. Highest-quality conviction signal in the report.
FII: 1.25% → 0.03% — foreign funds fully exited during losses.
DII: 7.88% → 3.33% — domestic institutions trimmed materially.
Public 24.67%. Shareholder count ~21,000. No pledge flagged.
Valuation metric: with negative earnings, P/B and EV/Sales on normalised revenue are the appropriate lenses. Scenarios anchor to recovery trajectory, normalised margin assumptions and the peer multiple range — they are analytical constructs, not price targets.
🔴 Bear
Assumption: Recovery stalls, CDMO lumpy, margins stay sub-5%, working capital keeps absorbing cash; book multiple de-rates toward ~2.5-3x.
Research-reference range: meaningfully below CMP. Prob ~25%.
🟡 Base
Assumption: Volume recovery continues, FY27 PAT break-even, OPM rebuilds to low-teens; market holds ~4x book on recovering BV.
Research-reference range: around-to-modestly-above CMP. Prob ~50%.
🟢 Bull
Assumption: CDMO scales with multi-year wins, OPM back toward high-teens, ROCE recovers; re-rating toward FY22 earnings power + premium.
Research-reference range: materially above CMP over 2-3Y. Prob ~25%.
Stage classification
The weekly chart shows a multi-year Stage 4 markdown (~₹990 → ₹512) bottoming through 2025 into an early Stage 1 accumulation base (Base Finder: Base Stage 1, depth ~12.7%). The recent move to ₹771 with an intraday spike to ₹850 is a base-breakout attempt.
Setup type
Bottoming base / early Stage-2 attempt. Price (₹771) is now above Fast EMA ₹693 & Mid EMA ₹699 but still below Slow EMA ₹970 — the long-term downtrend reference. Confirmation needs a decisive reclaim with volume.
| Signal | Reading | Interpretation |
|---|---|---|
| 1-Month change | +20.6% | Strong upward thrust |
| 1-Week change | +7.0% | Momentum building |
| YTD change | +7.8% | Net positive |
| Price vs Fast/Mid EMA (₹693/₹699) | Above | Near-term bullish |
| Price vs Slow EMA (₹970) | Below | LT trend not yet reclaimed |
| Weekly oscillators / MA score | 0.18 / 0.40 | Buy-leaning |
Volume: today's session showed an above-average spike (intraday high ₹850 vs close ₹771) — a wide-range bar to monitor for follow-through. Source: TradingView IN Analytics + Screener TA.
| Level | Price ₹ | Basis |
|---|---|---|
| 52-Week High | 991 | Prior swing high / supply |
| Resistance 2 | ~925 | Upper circuit ref / Slow-EMA zone approach |
| Resistance 1 | ~850 | Today's intraday high — immediate supply |
| CMP | 771 | Above Fast/Mid EMA |
| Support 1 | ~693–699 | Fast/Mid EMA confluence |
| Support 2 | ~617 | Lower circuit ref / base-low zone |
| 52-Week Low | 512 | Cycle trough |
All levels are research reference levels — not buy/sell signals.
| Symbol | TA Label | Score |
|---|---|---|
| NSE:ASTEC | Buy | +0.15 |
| NSE:IPL (India Pesticides) | Neutral | +0.01 |
| NSE:BHARATRAS | Neutral | −0.09 |
| NSE:PIIND (PI Industries) | Sell | −0.26 |
| NSE:RALLIS | Sell | −0.26 |
Astec ranks #1 in the peer set on combined daily+weekly TA — it is turning up while the larger, profitable names (PI Industries, Rallis) are technically rolling over. This relative-strength leadership at a fundamental trough is the notable technical feature of the setup.
Basis: T1 = today's high/supply; T2 = 52W-high & slow-EMA zone; invalidation = base-low / lower-circuit reference. Reference levels only.
✅ Confirms thesis
Weekly close above ₹850 on above-average volume; reclaim of Slow EMA (~₹970) would confirm Stage-2 transition.
🔴 Invalidates thesis
Weekly close below ₹615 (base low / lower circuit zone) breaks the accumulation structure and reopens the prior downtrend.
Sourced directly from the IN Analytics & Base Finder studies on the TradingView Desktop FUNDAMENTALS workspace (29 May 2026).
| Indicator | Value | Read |
|---|---|---|
| Fast EMA | ₹693.21 | Price above — near-term support |
| Mid EMA | ₹698.95 | Price above |
| Slow EMA | ₹969.95 | Price below — LT downtrend ref |
| Base Finder — Stage | Stage 1 | Accumulation base |
| Base depth | 12.67% | Tight base |
| 1-Month momentum | +20.6% | Strong thrust |
| Upper / Lower circuit | ₹925 / ₹617 | Daily band reference |
Astec Lifesciences is a Godrej-controlled triazole-fungicide technicals and CDMO maker emerging from a severe agrochemical destocking trough. FY26 marks the inflection — revenue +17.6%, EBITDA back to positive, and a ₹238 Cr rights issue that cut D/E from 2.36x to 1.15x while the promoter raised its stake to ~72%. The setup pairs a fundamental bottom (still loss-making, ROCE −5%, 202 debtor days) with an improving technical base that leads its peer group. The thesis is a multi-quarter recovery play whose proof points are PAT break-even and working-capital normalisation, against the risk of a rich 4.4x book multiple if the turn stalls.